This phase II trial studies how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in participants with acute myeloid leukemia. Antibody-drug conjugates, such as gemtuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells.
Name: Gemtuzumab Ozogamicin
Description: Receive IVType: DrugTreatment (gemtuzumab ozogamicin)
Name: Quality-of-Life Assessment
Description: Ancillary studiesType: OtherTreatment (gemtuzumab ozogamicin)
Description: Measured by clearance of measurable residual disease (MRD) with bone marrow evaluation after one or two cycles of therapy and compare responses (rate of eradication of MRD) based on CD33 single nucleotide polymorphism rs12459419 genotype.
Measure: Clinical response rate Time: Up to 70 daysDescription: Measured by grade III/IV non-hematologic toxicities using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.
Measure: Rate of sinusoidal obstructive syndrome (SOS) Time: Up to 6 monthsDescription: Measured by those receiving HCT
Measure: Rate of allogeneic hematopoietic cell transplantation (HCT) Time: Up to 6 MonthsSingle Group Assignment
There is one SNP
Measured by clearance of measurable residual disease (MRD) with bone marrow evaluation after one or two cycles of therapy and compare responses (rate of eradication of MRD) based on CD33 single nucleotide polymorphism rs12459419 genotype.. Rate of sinusoidal obstructive syndrome (SOS).